[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1210792A1 - Molecules with antigen binding and polyvalent fc gamma receptor binding activity - Google Patents

Molecules with antigen binding and polyvalent fc gamma receptor binding activity Download PDF

Info

Publication number
HK1210792A1
HK1210792A1 HK15111563.7A HK15111563A HK1210792A1 HK 1210792 A1 HK1210792 A1 HK 1210792A1 HK 15111563 A HK15111563 A HK 15111563A HK 1210792 A1 HK1210792 A1 HK 1210792A1
Authority
HK
Hong Kong
Prior art keywords
polyvalent
molecules
gamma receptor
stradobodies
antigen binding
Prior art date
Application number
HK15111563.7A
Other languages
English (en)
Chinese (zh)
Inventor
Block David
Olsen Henrik
Original Assignee
Gliknik Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliknik Inc. filed Critical Gliknik Inc.
Publication of HK1210792A1 publication Critical patent/HK1210792A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
HK15111563.7A 2012-08-20 2013-08-20 Molecules with antigen binding and polyvalent fc gamma receptor binding activity HK1210792A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261691057P 2012-08-20 2012-08-20
US61/691,057 2012-08-20
US201361785144P 2013-03-14 2013-03-14
US61/785,144 2013-03-14
PCT/US2013/055800 WO2014031646A2 (en) 2012-08-20 2013-08-20 Molecules with antigen binding and polyvalent fc gamma receptor binding activity

Publications (1)

Publication Number Publication Date
HK1210792A1 true HK1210792A1 (en) 2016-05-06

Family

ID=50150476

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111563.7A HK1210792A1 (en) 2012-08-20 2013-08-20 Molecules with antigen binding and polyvalent fc gamma receptor binding activity

Country Status (13)

Country Link
US (2) US9683044B2 (es)
EP (1) EP2885320A4 (es)
JP (1) JP2015527366A (es)
KR (1) KR20150058236A (es)
CN (1) CN104718223A (es)
AU (1) AU2013305885B2 (es)
BR (1) BR112015003459A2 (es)
CA (1) CA2882296A1 (es)
HK (1) HK1210792A1 (es)
IL (1) IL237307A0 (es)
MX (1) MX2015002269A (es)
RU (1) RU2015109591A (es)
WO (1) WO2014031646A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151088A2 (en) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
EP2885320A4 (en) * 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY
CA2939198A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2016073917A1 (en) * 2014-11-06 2016-05-12 Gliknik Inc. Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose
JP2018510864A (ja) * 2015-03-10 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
IL314842A (en) 2015-07-24 2024-10-01 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
US10653790B2 (en) * 2015-07-29 2020-05-19 Nanotics, Llc Compositions and methods related to scavenger particles
CN106554968A (zh) * 2015-09-29 2017-04-05 中国农业科学院上海兽医研究所 日本血吸虫重组蛋白及其制备方法和应用
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CN110699371A (zh) * 2016-03-18 2020-01-17 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
MX2018011865A (es) * 2016-03-30 2019-03-28 Ab biosciences inc Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso.
US11155640B2 (en) 2016-05-23 2021-10-26 Janssen Biotech, Inc. Compositions and methods related to engineered Fc constructs
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
KR20190070977A (ko) 2016-11-01 2019-06-21 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
KR20240162607A (ko) 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
BR112019013955A2 (pt) * 2017-01-06 2020-02-11 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos de fc manipulados
UA128814C2 (uk) 2017-02-10 2024-10-30 Генмаб Б.В. Поліпептид та його застосування
JP2021502360A (ja) * 2017-11-09 2021-01-28 メディミューン，エルエルシー 二重特異的融合ポリペプチド及びその使用方法
US20210107988A1 (en) 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
KR20210008380A (ko) 2018-05-03 2021-01-21 젠맵 비. 브이 항체 변이체 조합물 및 그의 용도
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
EP3820518A4 (en) * 2018-07-11 2022-06-29 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
BR112021000392A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
EP3820890A1 (en) 2018-07-13 2021-05-19 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
EP3820900A1 (en) 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
JP2022531894A (ja) 2019-05-09 2022-07-12 ゲンマブ ビー．ブイ． がんの処置において使用するための抗ｄｒ５抗体の組み合わせの投与レジメン
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
EP4090366A1 (en) 2020-01-16 2022-11-23 Genmab A/S Formulations of cd38 antibodies and uses thereof
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
MX2023003749A (es) 2020-10-02 2023-04-24 Genmab As Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).
EP4399227A1 (en) 2021-09-06 2024-07-17 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
AU2023269546A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
CN119451985A (zh) 2022-05-12 2025-02-14 健玛保 在组合疗法中能够结合cd27的结合剂
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
KR20240156564A (ko) * 2023-04-21 2024-10-30 상트네어바이오사이언스 주식회사 두 개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2331607A1 (en) 1998-05-06 1999-11-11 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fc.gamma.ri receptor
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DE60127933T2 (de) 2000-01-03 2008-02-07 Mark L. Merion Station Tykocinski Chimäre proteine und anwendungen
ATE359812T1 (de) 2001-01-12 2007-05-15 Becton Dickinson Co Intrinsische fluoreszierende, selbstmultimerisierende mhc-fusionsproteine und deren komplexe
US7511121B2 (en) 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
AU2002315052A1 (en) 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
WO2003105898A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
AU2004224122A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Improved Fc fusion proteins
CA2527878A1 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
CN1723220A (zh) 2003-11-13 2006-01-18 韩美药品工业株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
JP2008506493A (ja) 2004-07-19 2008-03-06 エルテックス リミテッド 活性物質が表面に結合している修飾された導電性表面およびその使用
EP1824979A2 (en) 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
WO2006113889A2 (en) 2005-04-19 2006-10-26 University Of Maryland Compositions and methods for modulating interleukin-10
PT2439273T (pt) 2005-05-09 2019-05-13 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd- 1) e métodos para o tratamento de cancro utilizando anticorpos anti-pd-1 isoladamente ou em combinação com outros imunoterapêuticos
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
AU2007216170A1 (en) 2006-02-17 2007-08-23 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating CCR5/CCR5 ligands associated diseases
WO2007100083A1 (ja) 2006-03-03 2007-09-07 Tokyo University Of Science 生物活性を強化した抗体改変体
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
ES2619332T3 (es) 2007-05-11 2017-06-26 Alexion Pharmaceuticals, Inc. Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
WO2008151088A2 (en) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
CA2699944C (en) * 2007-09-21 2017-11-14 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
CN102648212B (zh) 2009-11-13 2014-12-03 基立福疗法公司 包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
AU2013211824B2 (en) 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
EP2885320A4 (en) * 2012-08-20 2016-04-06 Gliknik Inc MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY

Also Published As

Publication number Publication date
US20180094061A1 (en) 2018-04-05
JP2015527366A (ja) 2015-09-17
IL237307A0 (en) 2015-04-30
CA2882296A1 (en) 2014-02-27
US9683044B2 (en) 2017-06-20
BR112015003459A2 (pt) 2017-09-26
KR20150058236A (ko) 2015-05-28
EP2885320A2 (en) 2015-06-24
WO2014031646A2 (en) 2014-02-27
CN104718223A (zh) 2015-06-17
US20140072582A1 (en) 2014-03-13
AU2013305885B2 (en) 2017-12-21
EP2885320A4 (en) 2016-04-06
WO2014031646A3 (en) 2014-05-01
AU2013305885A1 (en) 2015-03-05
RU2015109591A (ru) 2016-10-20
MX2015002269A (es) 2015-07-06

Similar Documents

Publication Publication Date Title
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
MY165273A (en) Anti-cd48 antibodies and uses thereof
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
EA201290589A1 (ru) Cd127-связывающие белки
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201501063A1 (ru) СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201590294A1 (ru) Аналоги глюкагона
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX2015004105A (es) Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201590247A1 (ru) Антитела к siglec-15
EA201390813A1 (ru) Антитела и их применение
WO2014205302A3 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
NZ626242A (en) Anti-asic1 antibodies and uses thereof
EA201500363A8 (ru) Человеческие анти-vegfr-2/kdr-антитела
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
EA201591898A1 (ru) Антитела, направленные на m-csf
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof